hydroxychloroquine has been researched along with Blood Pressure, High in 44 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate the therapeutic benefit of cyclosporin A (CSA) switching to hydroxychloroquine (HCQ) in patients with rheumatoid arthritis (RA)." | 9.09 | Treatment with cyclosporin switching to hydroxychloroquine in patients with rheumatoid arthritis. ( Cho, CS; Kim, HY; Kim, WU; Lee, SK; Lee, WK; Paek, SI; Park, SH; Seo, YI; Song, HH, 2001) |
| "We conclude that hydroxychloroquine alleviated hypertension, proteinuria, and normalized soluble fms-like kinase-1 and endothelin-1 levels in our preeclampsia model and that these changes may involve the restoration of endothelial dysfunction; thus, hydroxychloroquine could potentially be used for preventing preeclampsia, even in the absence of lupus." | 8.12 | Hydroxychloroquine reduces hypertension and soluble fms-like kinase-1 in a Nω-nitro-l-arginine methyl ester-induced preeclampsia rat model. ( Byun, N; Cho, GJ; Choi, M; Choi, SJ; Hwang, JR; Kim, JS; Oh, SY; Roh, CR; Seok, YS; Sung, JH, 2022) |
| "To investigate the therapeutic benefit of cyclosporin A (CSA) switching to hydroxychloroquine (HCQ) in patients with rheumatoid arthritis (RA)." | 5.09 | Treatment with cyclosporin switching to hydroxychloroquine in patients with rheumatoid arthritis. ( Cho, CS; Kim, HY; Kim, WU; Lee, SK; Lee, WK; Paek, SI; Park, SH; Seo, YI; Song, HH, 2001) |
| "We conclude that hydroxychloroquine alleviated hypertension, proteinuria, and normalized soluble fms-like kinase-1 and endothelin-1 levels in our preeclampsia model and that these changes may involve the restoration of endothelial dysfunction; thus, hydroxychloroquine could potentially be used for preventing preeclampsia, even in the absence of lupus." | 4.12 | Hydroxychloroquine reduces hypertension and soluble fms-like kinase-1 in a Nω-nitro-l-arginine methyl ester-induced preeclampsia rat model. ( Byun, N; Cho, GJ; Choi, M; Choi, SJ; Hwang, JR; Kim, JS; Oh, SY; Roh, CR; Seok, YS; Sung, JH, 2022) |
| "To investigate whether hydroxychloroquine treatment is associated with major adverse cardiovascular events (MACE) (myocardial infarction, ischemic stroke, or cardiovascular-associated death) in patients with cutaneous LE (CLE) or systemic LE (SLE)." | 4.02 | Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study. ( Dreyer, L; Egeberg, A; Gislason, G; Haugaard, JH; Kofoed, K; Ottosen, MB, 2021) |
| "A 71-year old gentleman with history of arterial hypertension treated with valsartan presented on was hospitalized at the Infectious Diseases Unit, University of Bologna (Italy) for severe acute respiratory syndrome- coronavirus-2 (SARS-CoV-2) and received treatment with hydroxychloroquine 200mg bid (400 mg bid the first day), azithromycin 400 mg qd, thrombotic prophylaxis with enoxaparin 4000 UI qd and Venturi mask oxygen delivering FiO2 of 31%." | 3.96 | Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin. ( Bartoletti, M; Viale, P, 2020) |
| " Patients treated with leflunomide had increases in BP and a greater risk of incident hypertension compared with patients treated with methotrexate (hazard ratio, 1." | 3.88 | Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure. ( Baker, JF; Cannella, A; Cannon, GW; Caplan, L; Davis, LA; England, BR; George, M; Ibrahim, S; Michaud, K; Mikuls, TR; OʼDell, J; Sauer, B; Teng, CC, 2018) |
| "To compare the risk of incident hypertension between initiators of tumor necrosis factor (TNF)-α inhibitors and initiators of nonbiologic disease modifying antirheumatic drugs (hereafter referred to as nonbiologics) in rheumatoid arthritis patients taking methotrexate monotherapy." | 3.83 | Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis. ( Danaei, G; Desai, RJ; Kim, SC; Liao, KP; Schneeweiss, S; Solomon, DH, 2016) |
| " Subcutaneous administration of methotrexate was more effective than the oral administration at the same dosage in patients suffering from active rheumatoid arthritis." | 3.74 | [What's new in internal medicine?]. ( Francès, C, 2008) |
| "Patients with systemic lupus erythematosus (SLE) have increased cardiovascular morbidity and mortality." | 2.77 | QT dispersion in patients with systemic lupus erythematosus: the impact of disease activity. ( Ghahartars, M; Kojuri, J; Liaghat, L; Mahmoody, Y; Nazarinia, MA; Rezaian, Gr, 2012) |
| "Hypertension and chronic obstructive pulmonary disease were also related to admission." | 1.62 | Biological markers and follow-up after discharge home of patients with COVID-19 pneumonia. ( Andrés, EM; Domínguez García, MJ; Gutiérrez Gabriel, S; Moreno García, N; Pérez Mañas, G; Silvan Domínguez, M, 2021) |
| "The worldwide incidence of coronavirus disease 2019 (COVID-19) infection is rapidly increasing, but there exists limited information on coronavirus disease 2019 in pregnancy." | 1.56 | Coronavirus disease 2019 in pregnancy: early lessons. ( Baptiste, C; Breslin, N; D'Alton, M; Fuchs, K; Goffman, D; Gyamfi-Bannerman, C; Miller, R, 2020) |
| "Since December 2019, Coronavirus Disease 2019 (COVID-19) has emerged as a global pandemic." | 1.56 | Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients. ( Gao, C; Jin, CC; Tong, YX; Xiao, AT; Zhang, S; Zhu, L, 2020) |
| "Hydroxychloroquine was associated with significantly lower BPV." | 1.56 | Blood Pressure Variability and Age-related Blood Pressure Patterns in Systemic Lupus Erythematosus. ( Magder, LS; Petri, M; Stojan, G, 2020) |
| "Childhood-onset systemic lupus erythematosus (SLE) is a severe, lifelong, multisystem autoimmune disease." | 1.51 | Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus. ( Bijl, M; Bultink, IEM; de Leeuw, K; Dolhain, RJEM; Fritsch-Stork, R; Groot, N; Kamphuis, S; Shaikhani, D; Teng, YKO; Zirkzee, E, 2019) |
| "We hypothesized that patients with systemic lupus erythematosus (SLE) have greater blood pressure visit-to-visit variability than control subjects and that blood pressure visit-to-visit variability is associated with a higher comorbidity burden." | 1.51 | Increased blood pressure visit-to-visit variability in patients with systemic lupus erythematosus: association with inflammation and comorbidity burden. ( Barker, KA; Barnado, A; Chung, CP; Dickson, AL; Dupont, WD; Gandelman, JS; Khan, OA; Neal, JE; Reese, T; Shuey, MM; Stein, CM, 2019) |
| "Hydroxychloroquine was the most frequently filled DMARD (13." | 1.46 | End-stage renal disease in patients with rheumatoid arthritis. ( Bethel, M; Brown, S; Carbone, L; Chen, CC; Nahman, NS; Paudyal, S; Rice, C; Skelton, M; Yang, FM, 2017) |
| "Hydroxychloroquine-treated lupus patients showed a lower incidence of thromboembolic disease." | 1.40 | Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus. ( Algieri, F; Duarte, J; Gálvez, J; Gómez-Guzmán, M; Gómez-Morales, M; Jiménez, R; López-Farré, AJ; O'Valle, F; Pérez-Vizcaino, F; Romero, M; Sabio, JM; Sánchez, M; Zarzuelo, MJ, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.27) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (11.36) | 29.6817 |
| 2010's | 11 (25.00) | 24.3611 |
| 2020's | 27 (61.36) | 2.80 |
| Authors | Studies |
|---|---|
| García, RD | 1 |
| Asensio, JA | 1 |
| Perdicaro, DJ | 1 |
| de Los Ángeles Peral, M | 1 |
| Clemmer, JS | 1 |
| Hillegass, WB | 1 |
| Taylor, EB | 1 |
| Fung, KW | 1 |
| Baik, SH | 1 |
| Baye, F | 1 |
| Zheng, Z | 1 |
| Huser, V | 1 |
| McDonald, CJ | 1 |
| Choi, M | 1 |
| Hwang, JR | 1 |
| Sung, JH | 1 |
| Byun, N | 1 |
| Seok, YS | 1 |
| Cho, GJ | 1 |
| Choi, SJ | 1 |
| Kim, JS | 2 |
| Oh, SY | 1 |
| Roh, CR | 1 |
| Corrêa, BSG | 1 |
| de Barros, S | 1 |
| Vaz, JB | 1 |
| Peres, MA | 1 |
| Uchiyama, MK | 1 |
| da Silva, AA | 1 |
| Furukawa, LNS | 1 |
| Lipworth, B | 1 |
| Chan, R | 1 |
| Lipworth, S | 1 |
| RuiWen Kuo, C | 1 |
| Khaddour, K | 1 |
| Sikora, A | 1 |
| Tahir, N | 1 |
| Nepomuceno, D | 1 |
| Huang, T | 1 |
| Dariya, B | 1 |
| Nagaraju, GP | 1 |
| Everaert, BR | 1 |
| Muylle, J | 1 |
| Bartholomeus Twickler, T | 1 |
| Vicenzi, M | 1 |
| Di Cosola, R | 1 |
| Ruscica, M | 1 |
| Ratti, A | 1 |
| Rota, I | 1 |
| Rota, F | 1 |
| Bollati, V | 1 |
| Aliberti, S | 1 |
| Blasi, F | 1 |
| Medetalibeyoğlu, A | 1 |
| Şenkal, N | 1 |
| Çapar, G | 1 |
| Köse, M | 1 |
| Tükek, T | 1 |
| Breslin, N | 1 |
| Baptiste, C | 1 |
| Miller, R | 1 |
| Fuchs, K | 1 |
| Goffman, D | 1 |
| Gyamfi-Bannerman, C | 1 |
| D'Alton, M | 1 |
| Viale, P | 1 |
| Bartoletti, M | 1 |
| Wang, Y | 1 |
| Foo, R | 1 |
| Thum, T | 1 |
| Santos, CS | 1 |
| Morales, CM | 1 |
| Álvarez, ED | 1 |
| Castro, CÁ | 1 |
| Robles, AL | 1 |
| Sandoval, TP | 1 |
| Rein, N | 1 |
| Haham, N | 1 |
| Orenbuch-Harroch, E | 1 |
| Romain, M | 1 |
| Argov, Z | 1 |
| Vaknin-Dembinsky, A | 1 |
| Gotkine, M | 1 |
| Choi, NH | 1 |
| Silver, ES | 1 |
| Fremed, M | 1 |
| Liberman, L | 1 |
| Patel, M | 1 |
| Gangemi, A | 1 |
| Marron, R | 1 |
| Chowdhury, J | 1 |
| Yousef, I | 1 |
| Zheng, M | 1 |
| Mills, N | 1 |
| Tragesser, L | 1 |
| Giurintano, J | 1 |
| Gupta, R | 1 |
| Gordon, M | 1 |
| Rali, P | 1 |
| D'Alonso, G | 1 |
| Fleece, D | 1 |
| Zhao, H | 1 |
| Patlakh, N | 1 |
| Criner, G | 1 |
| García-Saavedra, MB | 1 |
| Rosales-Gutiérrez, RR | 1 |
| Valverde, E | 1 |
| Chumbes-Aguirre, M | 1 |
| Alvarado, R | 1 |
| Polo, R | 1 |
| Azañero, R | 1 |
| Chávez, C | 1 |
| Sobol, I | 1 |
| Yuzefpolskaya, M | 1 |
| Roth, Z | 1 |
| Colombo, PC | 1 |
| Horn, E | 1 |
| Takeda, K | 1 |
| Sayer, G | 1 |
| Uriel, N | 1 |
| Naka, Y | 1 |
| Brusasco, C | 1 |
| Corradi, F | 1 |
| Di Domenico, A | 1 |
| Raggi, F | 1 |
| Timossi, G | 1 |
| Santori, G | 1 |
| Brusasco, V | 1 |
| Gao, C | 1 |
| Zhu, L | 1 |
| Jin, CC | 1 |
| Tong, YX | 1 |
| Xiao, AT | 1 |
| Zhang, S | 1 |
| Riou, M | 1 |
| Marcot, C | 1 |
| Canuet, M | 1 |
| Renaud-Picard, B | 1 |
| Chatron, E | 1 |
| Porzio, M | 1 |
| Dégot, T | 1 |
| Hirschi, S | 1 |
| Metz-Favre, C | 1 |
| Kassegne, L | 1 |
| Ederle, C | 1 |
| Khayath, N | 1 |
| Labani, A | 1 |
| Leyendecker, P | 1 |
| De Blay, F | 1 |
| Kessler, R | 1 |
| Haugaard, JH | 1 |
| Dreyer, L | 1 |
| Ottosen, MB | 1 |
| Gislason, G | 1 |
| Kofoed, K | 1 |
| Egeberg, A | 1 |
| Lee, KH | 1 |
| Hong, SH | 1 |
| Seong, D | 1 |
| Choi, YR | 1 |
| Ahn, YT | 1 |
| Kim, KS | 1 |
| Kim, SE | 1 |
| Lee, S | 1 |
| Sim, W | 1 |
| Kim, D | 1 |
| Jun, B | 1 |
| Yang, JW | 1 |
| Yon, DK | 1 |
| Lee, SW | 1 |
| Kim, MS | 1 |
| Dragioti, E | 1 |
| Li, H | 1 |
| Jacob, L | 1 |
| Koyanagi, A | 1 |
| Abou Ghayda, R | 1 |
| Shin, JI | 1 |
| Smith, L | 1 |
| Gutiérrez Gabriel, S | 1 |
| Domínguez García, MJ | 1 |
| Pérez Mañas, G | 1 |
| Moreno García, N | 1 |
| Silvan Domínguez, M | 1 |
| Andrés, EM | 1 |
| Baker, JF | 1 |
| Sauer, B | 1 |
| Teng, CC | 1 |
| George, M | 1 |
| Cannon, GW | 1 |
| Ibrahim, S | 1 |
| Cannella, A | 1 |
| England, BR | 1 |
| Michaud, K | 1 |
| Caplan, L | 1 |
| Davis, LA | 1 |
| OʼDell, J | 1 |
| Mikuls, TR | 1 |
| Groot, N | 1 |
| Shaikhani, D | 1 |
| Teng, YKO | 1 |
| de Leeuw, K | 1 |
| Bijl, M | 1 |
| Dolhain, RJEM | 1 |
| Zirkzee, E | 1 |
| Fritsch-Stork, R | 1 |
| Bultink, IEM | 1 |
| Kamphuis, S | 1 |
| DeParis, SW | 1 |
| Joseph, SS | 1 |
| Stojan, G | 1 |
| Magder, LS | 1 |
| Petri, M | 1 |
| Reese, T | 1 |
| Dickson, AL | 1 |
| Shuey, MM | 1 |
| Gandelman, JS | 1 |
| Barnado, A | 1 |
| Barker, KA | 1 |
| Neal, JE | 1 |
| Khan, OA | 1 |
| Dupont, WD | 1 |
| Stein, CM | 1 |
| Chung, CP | 1 |
| Ekwom, PE | 1 |
| Gómez-Guzmán, M | 1 |
| Jiménez, R | 1 |
| Romero, M | 1 |
| Sánchez, M | 1 |
| Zarzuelo, MJ | 1 |
| Gómez-Morales, M | 1 |
| O'Valle, F | 1 |
| López-Farré, AJ | 1 |
| Algieri, F | 1 |
| Gálvez, J | 1 |
| Pérez-Vizcaino, F | 1 |
| Sabio, JM | 1 |
| Duarte, J | 1 |
| Joo, YB | 1 |
| Sung, YK | 1 |
| Shim, JS | 1 |
| Kim, JH | 1 |
| Lee, EK | 1 |
| Lee, HS | 1 |
| Bae, SC | 1 |
| Uutela, T | 1 |
| Kautiainen, H | 1 |
| Järvenpää, S | 1 |
| Salomaa, S | 1 |
| Hakala, M | 1 |
| Häkkinen, A | 1 |
| Desai, RJ | 1 |
| Solomon, DH | 1 |
| Schneeweiss, S | 1 |
| Danaei, G | 1 |
| Liao, KP | 1 |
| Kim, SC | 1 |
| Paudyal, S | 1 |
| Yang, FM | 1 |
| Rice, C | 1 |
| Chen, CC | 1 |
| Skelton, M | 1 |
| Bethel, M | 1 |
| Brown, S | 1 |
| Nahman, NS | 1 |
| Carbone, L | 1 |
| Francès, C | 1 |
| Kojuri, J | 1 |
| Nazarinia, MA | 1 |
| Ghahartars, M | 1 |
| Mahmoody, Y | 1 |
| Rezaian, Gr | 1 |
| Liaghat, L | 1 |
| McLaurin, EY | 1 |
| Holliday, SL | 1 |
| Williams, P | 1 |
| Brey, RL | 1 |
| Mittal, BV | 1 |
| Pendse, S | 1 |
| Rennke, HG | 1 |
| Singh, AK | 1 |
| Tanay, A | 1 |
| Leibovitz, E | 1 |
| Frayman, A | 1 |
| Zimlichman, R | 1 |
| Shargorodsky, M | 1 |
| Gavish, D | 1 |
| Kim, WU | 1 |
| Seo, YI | 1 |
| Park, SH | 1 |
| Lee, WK | 1 |
| Lee, SK | 1 |
| Paek, SI | 1 |
| Cho, CS | 1 |
| Song, HH | 1 |
| Kim, HY | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Secondary Event Prevention Using Population Risk Management After PCI[NCT02694185] | 5,269 participants (Actual) | Interventional | 2016-10-01 | Active, not recruiting | |||
| QT Dispersion in Patients With Systemic Lupus Erythematosus: the Impact of Disease Activity[NCT01031797] | 124 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| Hydroxychloroquine Assessment of Management Study in Coronary Artery Disease After Angiography.[NCT02874287] | Phase 4 | 35 participants (Actual) | Interventional | 2017-10-08 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Cardiovascular Events (CVEs) such as mortality, myocardial infarction, stroke, or repeat revascularization among IHD patients at 12 months post-PCI and progressive erosive disease demonstrated in patients with rheumatic disease will be monitored. CVEs will be monitored to determine if there is a reduction in the occurrence of those events as a result of the intervention. (NCT02694185)
Timeframe: 1 year
| Intervention | Cardiovascular events (Mean) |
|---|---|
| Experimental Group | 15.2 |
| Control Group | 14.3 |
To establish the cost to implement and maintain the intervention, above the cost of usual care. Incremental Cost Effectiveness (ICE) is the cost to achieve a 10% improvement in PDC, and the cost of CVE prevented. (NCT02694185)
Timeframe: through study completion, an average of 1 year
| Intervention | dollars per patient (Median) |
|---|---|
| Experimental Group | 821.45 |
| Control Group | 893.55 |
Proportion of Days Covered (PDC) is measured by looking at the number of doses of medication a patient has versus days in the month (if a patient has 20 days of medication for a 30 day period their PDC is 20/30, 2/3, or 66.7%). Used to assess the effectiveness of the intervention, PDC will be tested among IHD patients in the year after PCI and among rheumatology clinic patients chronically prescribed DMARDs. (NCT02694185)
Timeframe: 1 year
| Intervention | percentage of days covered (Mean) | ||
|---|---|---|---|
| Anti-platelet | Beta-Blocker | Statin | |
| Control Group | 75.6 | 73.3 | 71.2 |
| Experimental Group | 82.6 | 78.4 | 78.8 |
4 reviews available for hydroxychloroquine and Blood Pressure, High
| Article | Year |
|---|---|
The Role of Inflammation as a Preponderant Risk Factor in Cardiovascular Diseases.
Topics: Anti-Inflammatory Agents; Antihypertensive Agents; Cardiovascular Diseases; Humans; Hydroxychloroqui | 2022 |
Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Betacoronavirus; Comorbid | 2020 |
[Cardiovascular implications of SARS-CoV-2 infection: A literature review].
Topics: Acute Coronary Syndrome; Algorithms; Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme | 2020 |
Risk factors of COVID-19 mortality: a systematic review of current literature and lessons from recent retracted articles.
Topics: Age Factors; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Asian Peopl | 2020 |
2 trials available for hydroxychloroquine and Blood Pressure, High
| Article | Year |
|---|---|
QT dispersion in patients with systemic lupus erythematosus: the impact of disease activity.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Echocardiography; Electrocardiography; Fema | 2012 |
Treatment with cyclosporin switching to hydroxychloroquine in patients with rheumatoid arthritis.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Cyclosporine; Female; Humans; Hydroxychloroquine | 2001 |
38 other studies available for hydroxychloroquine and Blood Pressure, High
| Article | Year |
|---|---|
Antihypertensive effects of immunosuppressive therapy in autoimmune disease.
Topics: Antihypertensive Agents; Female; Humans; Hydroxychloroquine; Hypertension; Immunosuppression Therapy | 2023 |
Effect of common maintenance drugs on the risk and severity of COVID-19 in elderly patients.
Topics: Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; COVID-19 Drug Trea | 2022 |
Hydroxychloroquine reduces hypertension and soluble fms-like kinase-1 in a Nω-nitro-l-arginine methyl ester-induced preeclampsia rat model.
Topics: Animals; Blood Pressure; Endothelial Cells; Endothelin-1; Female; Hydroxychloroquine; Hypertension; | 2022 |
COVID-19: Understanding the impact of anti-hypertensive drugs and hydroxychloroquine on the ACE1 and ACE2 in lung and adipose tissue in SHR and WKY rats.
Topics: Adipose Tissue; Angiotensin-Converting Enzyme 2; Animals; Antihypertensive Agents; Blood Pressure; C | 2023 |
Weathering the Cytokine Storm in Susceptible Patients with Severe SARS-CoV-2 Infection.
Topics: Administration, Inhalation; Adrenal Cortex Hormones; Age Factors; Angiotensin-Converting Enzyme Inhi | 2020 |
Case Report: The Importance of Novel Coronavirus Disease (COVID-19) and Coinfection with Other Respiratory Pathogens in the Current Pandemic.
Topics: Antibodies, Monoclonal, Humanized; Azithromycin; Betacoronavirus; Ceftriaxone; Chicago; Chronic Pain | 2020 |
Emerging cardiological issues during the COVID-19 pandemic.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Betacoronavirus; Coronary Artery Disease; Coronavirus Infect | 2020 |
The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients.
Topics: Aged; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Disease Progressio | 2020 |
Characteristics of the initial patients hospitalized for COVID-19: a single-center report
Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhi | 2020 |
Coronavirus disease 2019 in pregnancy: early lessons.
Topics: Acute Kidney Injury; Adult; Anesthesia, General; Anti-Bacterial Agents; Antihypertensive Agents; Azi | 2020 |
Clinical experience with therapeutic dose of Low-Molecular-Weight Heparin.
Topics: Aged; Anti-Inflammatory Agents; Anticoagulants; Antihypertensive Agents; Azithromycin; Combined Moda | 2020 |
Using "old" medications to fight new COVID-19: Re-purposing with a purpose.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme Inhibitors; Antiviral Agents; Betaco | 2020 |
Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiv | 2020 |
Description of 3 patients with myasthenia gravis and COVID-19.
Topics: Adult; Aged; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatmen | 2020 |
COVID-19 reveals Brugada pattern in an adolescent patient.
Topics: Antiviral Agents; Brugada Syndrome; C-Reactive Protein; Chest Pain; Consanguinity; Cough; COVID-19; | 2020 |
Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure.
Topics: Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antirheumat | 2020 |
Characteristics and Outcomes of Patients With a Left Ventricular Assist Device With Coronavirus Disease-19.
Topics: Adult; Aged; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Diabetes Mellitus; F | 2020 |
Continuous positive airway pressure in COVID-19 patients with moderate-to-severe respiratory failure.
Topics: Adult; Aged; Aged, 80 and over; Air Filters; Algorithms; Antibodies, Monoclonal, Humanized; Antirheu | 2021 |
Proinflammatory cytokines are associated with prolonged viral RNA shedding in COVID-19 patients.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; China; Comorbidity; COVID-19; COVID-19 Drug | 2020 |
Clinical characteristics of and outcomes for patients with COVID-19 and comorbid lung diseases primarily hospitalized in a conventional pulmonology unit: A retrospective study.
Topics: Aged; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Anticoagulants; Antiviral Agents; Ch | 2021 |
Use of hydroxychloroquine and risk of major adverse cardiovascular events in patients with lupus erythematosus: A Danish nationwide cohort study.
Topics: Adult; Brain Ischemia; Cardiovascular Diseases; Cohort Studies; Comorbidity; Confounding Factors, Ep | 2021 |
Biological markers and follow-up after discharge home of patients with COVID-19 pneumonia.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Comorbidity; COVID-19; COVID-19 Drug Treatment; Creatine | 2021 |
Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis Is Associated With Changes in Blood Pressure.
Topics: Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Pressure; Female; | 2018 |
Long-Term Clinical Outcomes in a Cohort of Adults With Childhood-Onset Systemic Lupus Erythematosus.
Topics: Adolescent; Adult; Age of Onset; Aged; Antibodies, Antiphospholipid; Antirheumatic Agents; Child; Ch | 2019 |
Bilateral Sequential Acute Proptosis in a Woman With No History of Trauma.
Topics: Acute Disease; Adult; Antirheumatic Agents; Drug Therapy, Combination; Enzyme Inhibitors; Exophthalm | 2019 |
Blood Pressure Variability and Age-related Blood Pressure Patterns in Systemic Lupus Erythematosus.
Topics: Adolescent; Adult; Age Factors; Aged; Aging; Antirheumatic Agents; Baltimore; Black or African Ameri | 2020 |
Increased blood pressure visit-to-visit variability in patients with systemic lupus erythematosus: association with inflammation and comorbidity burden.
Topics: Adrenal Cortex Hormones; Adult; Blood Pressure; Case-Control Studies; Comorbidity; Cyclophosphamide; | 2019 |
Systemic lupus erythematosus (SLE) at the Kenyatta National Hospital.
Topics: Adolescent; Adult; Antibodies, Antinuclear; Arthritis; Black People; Child; Data Collection; Diabete | 2013 |
Chronic hydroxychloroquine improves endothelial dysfunction and protects kidney in a mouse model of systemic lupus erythematosus.
Topics: Acute Kidney Injury; Animals; Blood Pressure; Disease Models, Animal; Endothelium, Vascular; Enzyme | 2014 |
Prevalence, incidence, and associated factors of avascular necrosis in Korean patients with systemic lupus erythematosus: a nationwide epidemiologic study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antirheumatic Agents; Cohort Studies; Comorbidity; Databases, | 2015 |
Patients with rheumatoid arthritis have better functional and working ability but poorer general health and higher comorbidity rates today than in the late 1990s.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Biological Produc | 2015 |
Tumor Necrosis Factor-α Inhibitor Use and the Risk of Incident Hypertension in Patients with Rheumatoid Arthritis.
Topics: Adalimumab; Adult; Antibodies, Monoclonal; Antirheumatic Agents; Arthritis, Rheumatoid; Azathioprine | 2016 |
End-stage renal disease in patients with rheumatoid arthritis.
Topics: Adalimumab; Adolescent; Adult; Amyloidosis; Antirheumatic Agents; Arthritis, Rheumatoid; Biological | 2017 |
[What's new in internal medicine?].
Topics: Animals; Antirheumatic Agents; Arthritis, Rheumatoid; Autoimmune Diseases; Bacteriophages; Body Mass | 2008 |
Predictors of cognitive dysfunction in patients with systemic lupus erythematosus.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antiphospholipid; Aspirin; Autoant | 2005 |
Hematuria in a patient with class IV lupus nephritis.
Topics: Antihypertensive Agents; Biopsy; Cyclophosphamide; El Salvador; Female; Follow-Up Studies; Glomerula | 2006 |
Vascular elasticity of systemic lupus erythematosus patients is associated with steroids and hydroxychloroquine treatment.
Topics: Adrenal Cortex Hormones; Antirheumatic Agents; Arteries; Diabetes Mellitus; Elasticity; Female; Huma | 2007 |
[Corticotherapy in rheumatoid polyarthritis].
Topics: Adrenocorticotropic Hormone; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Betamethasone; C | 1971 |